Boron Containing Patents (Class 546/13)
-
Publication number: 20140315861Abstract: Disclosed herein inter alia are Boron containing compounds and methods for treating infections related to antibiotic resistant microorganisms.Type: ApplicationFiled: April 14, 2014Publication date: October 23, 2014Applicants: The Regents of the University of California, Universita' Degli Studi di Modena e Reggio EmiliaInventors: Brian K. Shoichet, Fabio Prati, Emilia Caselli, Chiara Romagnoli, Oliv Eidam
-
Publication number: 20140309421Abstract: The present invention relates to processes and intermediates for the preparation of compounds useful as inhibitors of Janus kinases (JAK).Type: ApplicationFiled: June 25, 2014Publication date: October 16, 2014Inventors: Gerald J. Tanoury, Young Chun Jung, Derek Magdziak, Adam Looker, Billie J. Kline, Václav Jurcík, Beatriz Dominguez Olmo
-
Patent number: 8859504Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: GrantFiled: November 2, 2012Date of Patent: October 14, 2014Assignee: Millennium Pharmaceuticals, Inc.Inventors: Eric L. Elliott, Abu J. Ferdous, Michael J. Kaufman, Sonja A. Komar Lay, Debra L. Mazaik, Quentin J. McCubbin, Phuong M. Nguyen, Vaithianathan Palaniappan, Raymond D. Skwierczynski, Nobel T. Truong, Csanad M. Varga, Peter N. Zawaneh
-
Patent number: 8859771Abstract: An organic electroluminescent compound containing Iridium, preparation method thereof and an organic electroluminescent device are disclosed. The compound is represented by the structure (2), wherein, R is C1˜C4 alkyl. The structure of the compound contains bipyridine ligand, also carries alkoxy group and fluorine atom, which improves its carrier injection and transfer ability, and increases its internal quantum efficiency and electroluminescent efficiency. Furthermore, the compound uses strong field ligand 2-pyridine carboxylic acid as assistant ligand, which causes an effective blue shift of its emission spectrum and increases light-emitting efficiency of blue light phosphorescence greatly.Type: GrantFiled: June 30, 2011Date of Patent: October 14, 2014Assignee: Ocean's King Lighting Science & Technology Co., Ltd.Inventors: Mingjie Zhou, Ping Wang, Juanjuan Zhang, Zhenhua Zhang
-
Publication number: 20140256922Abstract: The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.Type: ApplicationFiled: May 16, 2014Publication date: September 11, 2014Inventors: Sunil David, Nikunj M. Shukla
-
Publication number: 20140256678Abstract: There are disclosed aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.Type: ApplicationFiled: May 20, 2014Publication date: September 11, 2014Applicant: Syntrix Biosystems, Inc.Inventors: Dean Y. Maeda, John A. Zebala, Aaron D. Schuler
-
Publication number: 20140256941Abstract: This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.Type: ApplicationFiled: March 5, 2014Publication date: September 11, 2014Applicant: Incyte CorporationInventors: Pingli Liu, Dengjin Wang, Yongzhong Wu, Ganfeng Cao, Michael Xia
-
Publication number: 20140248646Abstract: A fluorophore and methods of detecting cations and hydrophobic environments using the fluorophore are disclosed. The fluorophore includes an imidazo[1,5-a]pyridinium ion core and has the formula where R1, R2, R3 and X? are as defined in the specification, and n is an integer from 1 to 4.Type: ApplicationFiled: March 4, 2013Publication date: September 4, 2014Applicant: Indiana University Research and Technology CorporationInventor: Indiana University Research and Technology Corporation
-
Publication number: 20140249024Abstract: The present invention relates to pesticidal methods for the use and application of substituted 3-pyridyl thiazole compounds and the stereoisomers, salts, tautomers and N-oxides thereof and to compositions comprising the same. The invention also relates to insecticidal substituted 3-pyridyl thiazole compounds or of the compositions comprising such compounds for combating invertebrate pests and uses thereof. The substituted 3-pyridyl thiazole compounds of the present invention are defined by the following general formula (I): wherein R1, R2 A and m are defined as in the description.Type: ApplicationFiled: July 13, 2012Publication date: September 4, 2014Applicant: BASF SEInventors: Florian Kaiser, Gemma Veitch, Arun Narine, Joachim Dickhaut, Karsten Körber, Prashant Deshmukh, Nina Gertrud Bandur
-
Publication number: 20140243286Abstract: Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.Type: ApplicationFiled: February 28, 2014Publication date: August 28, 2014Applicant: Coferon, Inc.Inventors: Lee Daniel Arnold, Kenneth W. Foreman, Douglas S. Werner
-
Patent number: 8816081Abstract: Boron-comprising perylene monoimides and a process for producing the boron-comprising perylene monoimides are provided. The boron-comprising perylene monoimides are useful as building blocks for producing perylene monoimide derivatives and monoimide derivatives. The boron-comprising perylene monoimides are also useful for preparing dye-sensitized solar cells.Type: GrantFiled: August 5, 2013Date of Patent: August 26, 2014Assignees: BASF SE, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Henrike Wonneberger, Ingmar Bruder, Robert Send, Glauco Battagliarin, Chen Li, Klaus Muellen
-
Publication number: 20140221362Abstract: The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation.Type: ApplicationFiled: February 4, 2014Publication date: August 7, 2014Applicant: Bayer CropScience AGInventors: Thomas BRETSCHNEIDER, Martin Füßlein, Adeline Köhler, Friedrich August Mühlthau, Eva-Maria FRANKEN, Arnd VOERSTE
-
Publication number: 20140213554Abstract: Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.Type: ApplicationFiled: December 20, 2013Publication date: July 31, 2014Inventors: Guoxian Wu, Katrina Chan, Todd Ewing, Prabha N. Ibrahim, Jack Lin, Marika Nespi, Wayne Spevak, Ying Zhang
-
Patent number: 8791090Abstract: Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin.Type: GrantFiled: March 31, 2010Date of Patent: July 29, 2014Assignee: Kowa Company, Ltd.Inventors: Masanori Ashikawa, Junya Tagashira, Akiyasu Koketsu, Toshiharu Morimoto, Takahiro Kitamura, Syunji Takemura, Gen Watanabe, Tatsuaki Nishiyama, Satoshi Goda, Masaki Yamabi, Takeshi Doi, Hiroyuki Ishiwata
-
Patent number: 8791258Abstract: The present invention provides a novel class of pro-fluorescent probes for reactive oxygen species (ROS). One exemplary probe is mitochondria peroxy yellow 1 (MitoPY1), a new type of flurophore for imaging mitochondrial H2O2 in living cells with ROS and spatial specificity. The invention also provides methods of using pro-fluorescent probes to detect analytes. One exemplary method comprises using a pro-fluorescent probe of the invention to detect an explosive.Type: GrantFiled: June 8, 2009Date of Patent: July 29, 2014Assignee: The Regents of the University of CaliforniaInventor: Christopher J. Chang
-
Publication number: 20140206870Abstract: Herein are disclosed fluorescent dyes based around a framework for a ligand comprising a pyridyl group linked to a diaryl anilido unit. A variety of ligands based on this framework are disclosed. The ligands chelate to a BF2 center to produce the fluorescent dye. The disclosed dyes combine longer Stokes shifts (approximately 100 nm) with increased quantum yields. They are also photostable in aqueous and organic solutions for several hours. These dyes may be used in the labeling of biomolecules for bioimaging and assays. Also disclosed are methods for the synthesis of these dyes.Type: ApplicationFiled: August 10, 2012Publication date: July 24, 2014Applicant: UTI LIMITED PARTNERSHIPInventors: Warren Edward Piers, Juan Felipe Araneda
-
Publication number: 20140206647Abstract: There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.Type: ApplicationFiled: March 26, 2014Publication date: July 24, 2014Applicant: SYNTRIX BIOSYSTEMS, INC.Inventors: Dean Y. Maeda, John A. Zebala
-
Publication number: 20140206648Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronate compounds and their use as therapeutic agents.Type: ApplicationFiled: August 30, 2012Publication date: July 24, 2014Applicant: REMPEX PHARMACEUTICALS, INC.Inventors: Raja K. Reddy, Serge Henri Boyer, Maxim Totrov, Scott Hecker
-
Patent number: 8785651Abstract: The present invention relates to a method for manufacturing a boronic acid ester compound, characterized by reacting an aryl halide compound and a diboron ester compound in the presence of a nitrogen-containing organic base, a nickel catalyst, a phosphine compound and a solvent. According to the manufacturing method of the present invention, even if a nickel catalyst is used as the catalyst, a desired boronic acid ester compound can be obtained in a sufficiently high yield. Furthermore, even if aryl chloride or aryl bromide having relatively low price and low reactivity, was used as the aryl halide compound, a desired boronic acid ester compound can be obtained in a sufficiently high yield.Type: GrantFiled: March 24, 2009Date of Patent: July 22, 2014Assignees: Sumitomo Chemical Company, Limited, Genentech, Inc.Inventors: Takashi Miki, Yasuharu Shimasaki, Srinivasan Babu, Zhigang Cheng, Mark E. Reynolds, Qingping Tian
-
Publication number: 20140200198Abstract: Compounds, pharmaceutical formulations, and methods of treating anti-inflammatory conditions and/or helminth-associated diseases are disclosed.Type: ApplicationFiled: December 18, 2013Publication date: July 17, 2014Applicant: ANACOR PHARMACEUTICALS, INC.Inventors: Kurt Jarnagin, Tsutomu Akama
-
Publication number: 20140194385Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. Other embodiments relate to pharmaceutical compositions containing boronic acid derivatives and additional excipient such as meglumine.Type: ApplicationFiled: January 2, 2014Publication date: July 10, 2014Inventors: Raja K. Reddy, Tomasz Glinka, Maxim Totrov, Scott Hecker
-
Publication number: 20140194383Abstract: Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.Type: ApplicationFiled: April 9, 2012Publication date: July 10, 2014Applicants: Cornell University, Coferon, Inc., Purdue Research FoundationInventors: Francis Barany, Maneesh Pingle, Donald E. Bergstrom, Sarah F. Giardina, Lee Daniel Arnold
-
Publication number: 20140194384Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.Type: ApplicationFiled: January 2, 2014Publication date: July 10, 2014Inventors: Raja K. Reddy, Tomasz Glinka, Maxim Totrov, Scott Hecker
-
Publication number: 20140194387Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: ApplicationFiled: January 13, 2014Publication date: July 10, 2014Applicant: Millennium Pharmaceuticals, Inc.Inventors: Paul E. Fleming, Jing Li
-
Publication number: 20140194382Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.Type: ApplicationFiled: March 14, 2013Publication date: July 10, 2014Inventors: Raja Reddy, Tomasz Glinka, Maxim Totrov, Scott Hecker
-
Publication number: 20140194381Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.Type: ApplicationFiled: March 14, 2013Publication date: July 10, 2014Applicant: Rempex Pharmaceuticals, Inc.Inventor: Rempex Pharmaceuticals, Inc.
-
Publication number: 20140194386Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: ApplicationFiled: January 10, 2014Publication date: July 10, 2014Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT, Randy W. JACKSON
-
Publication number: 20140186875Abstract: The invention relates to compositions and methods useful in the labeling and identification of changes in protein levels, changes in enzyme activity, and changes in protein modification. The invention provides for highly soluble optical labeling molecules which are optionally cleavable after separation of mixtures of labeled proteins into components. These optical labeling molecules find utility in a variety of applications, including use in the field of proteomics.Type: ApplicationFiled: December 30, 2013Publication date: July 3, 2014Applicant: Montana State UniversityInventors: Edward Dratz, Paul Grieco
-
Publication number: 20140183504Abstract: A heteroarene derivative including a nitrogen-boron coordinate bond, represented by the following formula (1). In the formula (1). Z1 is a group represented by the following formula (2); Z2 is a substituted or unsubstituted aryl group including 6 to 30 ring carbon atoms or a substituted or unsubstituted heteroaryl group including 5 to 30 ring atoms; L is a substituted or unsubstituted arylene including 6 to 30 ring carbon atoms, a substituted or unsubstituted heteroarylene including 5 to 30 ring atoms, —O—, —S—, —(CR2R3)n— (wherein n is an integer of 1 to 8).Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Applicant: Idemitsu Kosan Co., Ltd.Inventors: Takushi SHIOMI, Kazuki NISHIMURA
-
Publication number: 20140179631Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: ApplicationFiled: February 25, 2014Publication date: June 26, 2014Applicant: Millennium Pharmaceuticals, Inc.Inventors: Paul E. Fleming, Jing Li
-
Publication number: 20140171390Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: ApplicationFiled: December 6, 2013Publication date: June 19, 2014Applicant: VenatoRx Pharmaceuticals, Inc.Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT
-
Publication number: 20140161729Abstract: The present invention is directed to method of using a collection of monomers capable of forming multimers as a fluorescence reporter in different applications such as ligand detection/screening, disease diagnosis, drug discovery or screening, fluorescent labeling and imaging, or other fluorescent methodologies. Each monomer in the collection includes one or more ligand elements useful for binding to a target molecule with a dissociation constant of less than 300 ?M and a linker element connected to the ligand elements directly or indirectly through a connector. Association of linker elements of different combinations of monomers, with their ligand elements bound to the target molecule to form a multimer, will generate a unique fluorescent signature different from that produced by those monomers either alone or in association with each other in the absence of the target molecule, when subjected to electromagnetic excitement.Type: ApplicationFiled: April 9, 2012Publication date: June 12, 2014Applicant: CORNELL UNIVERSITYInventors: Francis Barany, Maneesh Pingle, Donald E. Bergstrom, Sarah F. Giardina, Lee Daniel Arnold
-
Publication number: 20140155566Abstract: The invention relates to new compounds containing alkyl/alkenyl-cyano-borate or alkyl/alkenyl-cyano-fluoroborate anions, their preparation and their use, in particular as part of electrolyte formulations for electrochemical or optoelectronic devices.Type: ApplicationFiled: July 6, 2012Publication date: June 5, 2014Applicant: MERCK PATENT GMBHInventors: Nikolai (Mykola) Ignatyen, Michael Schulte, Kentaro Kawata, Tomohisa Goto, Jan Sprenger, Maik Finze, Walter Frank
-
Publication number: 20140148414Abstract: Prochelator compounds of Formula I or Formula II: are described, along with methods of using the same and pharmaceutical formulations or compositions containing the same.Type: ApplicationFiled: January 30, 2014Publication date: May 29, 2014Applicant: Duke UniversityInventors: Katherine J. Franz, Marina G. D. Leed
-
Patent number: 8735582Abstract: When phthalic acid is heated in heptane under azeotropic reflux conditions in the presence of a catalytic amount of an arylboronic acid compound (such as 2,6-(diisopropylaminomethyl)phenylboronic acid or 2,6-bis(diisopropylaminomethyl)phenylboronic acid), phthalic anhydride is obtained in high yield.Type: GrantFiled: March 3, 2010Date of Patent: May 27, 2014Assignee: National University Corporation Nagoya UniversityInventors: Kazuaki Ishihara, Akira Sakakura
-
Patent number: 8728486Abstract: The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.Type: GrantFiled: May 18, 2012Date of Patent: May 20, 2014Assignee: University of KansasInventors: Sunil A. David, Nikunj M. Shukla
-
Publication number: 20140134665Abstract: The invention relates generally to compositions and methods for the detection of zinc. In particular, compositions and methods are provided to detect changes in cellular zinc concentration and to correlate them to cellular phenomena.Type: ApplicationFiled: November 13, 2013Publication date: May 15, 2014Applicant: Northwestern UniversityInventors: Emily L. Que, Thomas V. O'Halloran, Teresa K. Woodruff
-
Publication number: 20140127137Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.Type: ApplicationFiled: June 17, 2013Publication date: May 8, 2014Applicant: Cercacor Laboratories, IncInventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
-
Patent number: 8716478Abstract: Compounds, pharmaceutical formulations, and methods of treating anti-inflammatory conditions and/or helminth-associated diseases are disclosed.Type: GrantFiled: January 27, 2011Date of Patent: May 6, 2014Assignee: Anacor Pharmaceuticals, Inc.Inventors: Kurt Jarnagin, Tsutomu Akama
-
Publication number: 20140121183Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.Type: ApplicationFiled: December 20, 2013Publication date: May 1, 2014Applicant: INFINITY PHARMACEUTICALS, INC.Inventors: Julian ADAMS, Mark L. Behnke, Alfredo C. Castro, Catherine A. Evans, Louis Grenier, Michael J. Grogan, Tao Liu, Daniel A. Snyder, Thomas T. Tibbitts
-
Publication number: 20140114074Abstract: The invention relates to a process for the preparation of alkali-metal salts with dihydridodicyanoborate anions by reaction of alkali-metal tetrahydridoborates or trihydridocyanoborates with trialkylsilyl cyanide and further reaction thereof in metathesis reactions.Type: ApplicationFiled: May 23, 2012Publication date: April 24, 2014Applicant: MERCK PATENT GmbHInventors: Nikolai (Mykola) Ignatyev, Michael Schulte, Eduard Bernhardt, Vera Bernhardt-Pitchougina, Helge Willner
-
Patent number: 8703743Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: GrantFiled: July 3, 2013Date of Patent: April 22, 2014Assignee: Millennium Pharmaceuticals, Inc.Inventors: Paul E. Fleming, Jing Li
-
Publication number: 20140107341Abstract: The present invention relates to compounds containing hydrido-tricyano-borate anions, their preparation and their use, in particular as part of electrolyte formulations for electrochemical or optoelectronic devices.Type: ApplicationFiled: May 23, 2012Publication date: April 17, 2014Applicant: MERCK PATENT GMBHInventors: Nikolai (Mykola) Ignatyev, Michael Schulte, Kentaro Kawata, Tomohisa Goto, Eduard Bernhardt, Vera Bernhardt-pitchougina, Helge Willner
-
Publication number: 20140102365Abstract: Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising nitrogen-containing ligands are provided. Also provided are nitrogen-containing ligands useful in the methods of the invention and metal coordination complexes comprising these ligands.Type: ApplicationFiled: December 19, 2013Publication date: April 17, 2014Inventors: Jeffrey W. Anthis, David Thompson
-
Patent number: 8696933Abstract: Polar nematic compounds, one example of which has the following structure: is a caged boron structure, where the sphere of the caged boron structure is C and each non-sphere vertex of the caged boron structure is B—H. R is H, an alkyl, a cycloalkyl, a bicycloalkyl, an alkenyl, a cycloalkenyl, a bicycloalkenyl, an alkynyl, an acyl, an aryl, an alkylaryl, a halogen, a cyano group, or an isothiocyanoto group, or R is a group that forms an ether, a ketone, an ester, a thioester, a sulfide, or a sulfone. X is COOR? or COSR?. R? is H, an alkyl, a cycloalkyl, a bicycloalkyl, an alkenyl, a cycloalkenyl, a bicycloalkenyl, an alkynyl, an aryl, a halogen, or a cyano group. The compounds may be used in liquid crystal displays (LCDs), and in television sets, laptop computers, computer monitors, hand-held communication devices, gaming devices, watches, cash registers, clocks, and calculators having liquid crystal displays.Type: GrantFiled: April 10, 2012Date of Patent: April 15, 2014Assignee: Vanderbilt UniversityInventors: Bryan Ringstrand, Piotr Kaszynski
-
Patent number: 8697872Abstract: Organoboron compounds are described that upon exposure to light absorb light and isomerize and form a dark-colored isomer. The dark-colored isomer converts back to the colorless isomer upon removal of light, or exposure to oxygen or heat. Such compounds can be added into polymeric matrices such as films. These compounds are suitable for UV-blocking, UV-detecting, and for oxygen-sensing applications. Uses include UV-blocking windows, sunglasses, and as indicators in packaging such as food packaging.Type: GrantFiled: March 29, 2012Date of Patent: April 15, 2014Assignee: Queen's University at KingstonInventors: Suning Wang, Hazem Y. S. Amarne, Yingli Rao
-
Patent number: 8691990Abstract: Compounds of formula (I): in which: X, R1, R2, R3 and R4 are as defined in the disclosure, or an acid addition salt thereof; and therapeutic use thereof.Type: GrantFiled: October 10, 2012Date of Patent: April 8, 2014Assignee: SanofiInventor: Jean-Francois Peyronel
-
Publication number: 20140084260Abstract: In certain embodiments, the invention provides boron-nitrogen heterocycles having Formula (I): wherein one of the E1 and E2 is N, and one of the E1 and E2 is B; wherein E3 and E4 is carbon; wherein ring Y and ring Z are 5-membered or 6-membered carbocyclic or heterocyclic aromatic ring fused to ring X; wherein R2 and R3 represent mono, di, tri, tetra substitutions or no substitution; wherein R2 and R3 are each independently selected from various substituents; and wherein any two adjacent R2, and R3 are optionally joined to form a ring, which may be further substituted. In certain embodiments, the invention provides devices, such as organic light emitting devices, that comprise such boron-nitrogen heterocycles.Type: ApplicationFiled: March 6, 2013Publication date: March 27, 2014Applicant: Universal Display CorporationInventors: Chuanjun Xia, Chun Lin
-
Patent number: 8680096Abstract: The invention relates to a formula (I), in which R is a hydrogen or halogen atom or a (C1-C6)alkyl group; X is one or more substituents selected from a hydrogen or halogen atom, a (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, cyano, hydroxy, or hydroxy(C1-C6)alkyl group; Y is a hydrogen or halogen atom or a (C1-C6)alkyl group; R1 is an NR2R3 or OR4 group; R2 and R3 independently are a hydrogen atom, a (C1-C6)alkyl, hydroxy(C1-C6)alkyl or oxo(C1-C6)alkyl group or R2 and R3, together with the nitrogen atom supporting the same, form a heterocycle optionally substituted by a (C1-C6)alkyl, hydroxy or oxo group; and R4 is a (C1-C6)alkyl, hydroxy(C1-C6)alkyl, or oxo(C1-C6)alkyl group, in the base or acid addition salt state. Said formula can be used therapeutically for treating or preventing diseases linked to the nuclear receptors Nurr-1, also known as NR4A2, NOT, TINUR, RNR-1, and HZF3.Type: GrantFiled: December 3, 2010Date of Patent: March 25, 2014Assignee: Sanofi-AventisInventors: Florian Auger, Luc Even
-
Publication number: 20140073785Abstract: Described are methods of forming protected boronic acids that provide in a manner that is straightforward, scalable, and cost-effective a wide variety of building blocks, such as building blocks containing complex and/or pharmaceutically important structures, and/or provide simple or complex protected organoboronic acid building blocks. A first method includes reacting an imino-di-carboxylic acid and an organoboronate salt. A second method includes reacting a N-substituted morpholine dione and an organoboronic acid.Type: ApplicationFiled: September 24, 2013Publication date: March 13, 2014Applicant: The Board of Trustees of the University of IllinoisInventors: Martin D. Burke, Graham R. Dick, David M. Knapp, Eric P. Gillis, Jenna A. Klubnick